Health Economics Unit, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Australian Genomics Health Alliance, Melbourne, Victoria, Australia; Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Health Economics Unit, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Australian Genomics Health Alliance, Melbourne, Victoria, Australia; Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Genet Med. 2022 May;24(5):1037-1044. doi: 10.1016/j.gim.2022.01.013. Epub 2022 Feb 16.
To evaluate whether the additional cost of providing increasingly faster genomic results in pediatric critical care is outweighed by reductions in health care costs and increases in personal utility.
Hospital costs and medical files from a cohort of 40 children were analyzed. The health economic impact of rapid and ultra-rapid genomic testing, with and without early initiation, relative to standard genomic testing was evaluated.
Shortening the time to results led to substantial economic and personal benefits. Early initiation of ultra-rapid genomic testing was the most cost-beneficial strategy, leading to a cost saving of AU$26,600 per child tested relative to standard genomic testing and a welfare gain of AU$12,000 per child tested. Implementation of early ultra-rapid testing of critically ill children is expected to lead to an annual cost saving of AU$7.3 million for the Australian health system and an aggregate welfare gain of AU$3.3 million, corresponding to a total net benefit of AU$10.6 million.
Early initiation of ultra-rapid genomic testing can offer substantial economic and personal benefits. Future implementation of rapid genomic testing programs should focus not only on optimizing the laboratory workflow to achieve a fast turnaround time but also on changing clinical practice to expedite test initiation.
评估在儿科重症监护中提供越来越快的基因组结果的额外成本是否超过了医疗成本的降低和个人效用的增加。
分析了 40 名儿童的住院费用和病历。评估了快速和超快速基因组检测（包括早期启动）与标准基因组检测相比的健康经济影响。
缩短结果时间带来了巨大的经济和个人利益。早期启动超快速基因组检测是最具成本效益的策略，与标准基因组检测相比，每个接受检测的儿童可节省 26600 澳元的成本，每个接受检测的儿童可获得 12000 澳元的福利收益。对危重症儿童进行早期超快速检测的实施预计将为澳大利亚卫生系统每年节省 730 万澳元的成本，并带来 330 万澳元的总福利收益，相当于总净收益 1060 万澳元。
早期启动超快速基因组检测可以带来巨大的经济和个人利益。未来快速基因组检测项目的实施不仅应侧重于优化实验室工作流程以实现快速周转时间，还应侧重于改变临床实践以加快检测启动。
